Supply Chain

The company brings its temperature-controlled Superbox to the US pharma industry, aiming to improve speed, compliance, and resilience in the cold chain process.

The company will participate in the Trump administration’s direct-to-patient drug platform, while committing $100 billion to US R&D and manufacturing.

The pharma giant will invest in a 35,000-square-foot RLT manufacturing site in Winter Park, FL as part of its $23 billion US infrastructure expansion.

The pharma giant becomes the latest manufacturer to participate in the Trump Administration’s direct-to-patient pricing platform, aligning US drug costs with European benchmarks while reinforcing its domestic manufacturing investments.

A new Foreign Trade Zone–enabled facility in Annville strengthens the company’s temperature-controlled, compliant logistics capabilities, while accelerating customs processing and last-mile healthcare delivery.

Merck’s decision to shutter its Riverside, PA antibiotic API facility underscores how decades of cost-driven optimization have eroded domestic manufacturing of essential medicines—exposing systemic vulnerabilities in US drug supply resilience that markets alone are unlikely to fix.

The healthcare pricing platform is expanding access to Novo Nordisk’s newly approved oral GLP-1 for weight management, pairing transparent cash pricing with telehealth support nationwide.

The sustainable packaging company relocates its branded foam production to a more expansive Lansing site, boosting capacity, efficiency, and support for growing demand in the life science market.

In the first part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, discusses growing concerns around cargo theft and fraud in healthcare logistics—and how enhanced security features and platform innovation are helping manufacturers protect chain of custody and compliance.

In the first part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, describes how the company uses deep customer relationships and cross-enterprise collaboration to develop new products and solutions that address evolving market dynamics, improve efficiency, and support healthier outcomes.

The acquisition strengthens Yusen Logistics’ healthcare footprint across Europe, adding specialized transportation, warehousing, digital, and GDP-compliant capabilities to its regional and global network.

As drugmakers experiment with direct-to-patient sales, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, shares why wholesalers remain indispensable to pharmaceutical distribution—supporting cold chain management, regulatory compliance, billing, and large-scale logistics that manufacturers are not equipped to handle on their own.

The South Korea–based CDMO acquires its first US manufacturing facility in Rockville, MD, expanding its global footprint and strengthening biologics capacity.

Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, describes why uncertainty around final tariff rules is forcing manufacturers into a wait-and-see position.

In today’s Pharma Pulse, major pharma players commit to most-favored-nation pricing, as DHL bolsters West Coast logistics for temperature-sensitive drugs.

A $1.5 million investment in its facilities located near Los Angeles International Airport strengthens DHL’s cold chain capacity, supporting pharmaceutical and healthcare shipments while advancing the company’s long-term health logistics strategy for the Americas.

The CDMO’s latest GMP-qualified line strengthens sterile manufacturing scalability.

In a discussion on global trade disruption, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, explains why pharmaceutical manufacturers must move beyond broad assumptions about tariffs and instead assess trade risk at the individual product level.

In today’s Pharma Pulse, House Republicans block a critical insurance subsidy extension, as new research highlights the oncology benefits of GLP-1s.

The acquisition strengthens CEVA’s global project logistics footprint, adding heavy-lift expertise, specialized engineering talent, and integrated solutions across key regions.

In today’s Pharma Pulse, Novartis and Moderna anchor a domestic manufacturing surge, while AI-driven biomarker discovery and physician well-being reshape the future of clinical care.

The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.

AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

As the FDA ends its phased exemption period for most trading partners, Two Labs’ Michael Rowe warns that DSCSA compliance is entering a far more complex era—one shaped by real-time traceability, digital record requirements, and a transition to a 12-digit NDC.